Vasorum gets FDA green light for its vascular closure device aimed at arterial punctures

Irish devicemaker Vasorum got FDA approval for its Celt ADC vascular closure device that is aimed at arterial puncture closure.

The device is indicated for both diagnostic and anticoagulated percutaneous interventional cardiology and radiology patients. A study of 207 interventional cardiology procedure patients that was conducted in four cardiology centers in the U.S. in Europe helped support the approval, the company said.

"With more than 20,000 patient implants to date in Europe, Celt ACD has proven itself to be a best in class arterial puncture closure device,”  Dr. James Coleman, co-founder and CEO of Vasorum, said in a statement. He added that the device “allows immediate closure of multiple re-sticks in calcified vessels and is also very comfortable for patients.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

More than 8 million catheter procedures are performed annually, which pegs the femoral artery closure device market at about $8 billion, the company estimated.

The number of procedures is expected to surpass 10 million in the next four years. On top of the number of interventional cardiology procedures, growth is also being fueled by more peripheral vascular, neuro-vascular and other catheter procedures that require more patient friendly devices and more efficient patient discharge from hospitals.

Cardiva Medical and Cardinal Health are also is a players in the vascular closure device arena.

-here’s the release

Read more:
Cardinal Health will snatch up Accessclosure for $320M
Vascular closure player Cardiva gets $12.5M, J&J exec to commercialize
Covidien plans to slash 183 jobs in NY plant closure

Suggested Articles

The FDA disclosed over 60 safety reports related to intra-aortic balloon pumps manufactured by Maquet and Datascope, following a recall this summer.

Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.